• Explore /
  • Poster
  • / Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.

Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.

Abstract Poster

Authors

null

Philipp Harter

Kliniken Essen-Mitte, and AGO, Essen, Germany

Philipp Harter , Marie-Ange Mouret-Reynier , Domenica Lorusso , Claire Cropet , Eva M. Guerra , Pia Wolfrum-Ristau , Takashi Matsumoto , Ignace Vergote , Nicoletta Colombo , Johanna Unelma Maenpaa , Coriolan Lebreton , Nikolaus de Gregorio , Anna Maria Mosconi , Maria Jesús Rubio-Pérez , Hugues Bourgeois , Peter A. Fasching , Anne-Claire Hardy-Bessard , Dominik Denschlag , Eric Pujade-Lauraine , Isabelle Laure Ray-Coquard

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02477644

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5550)

DOI

10.1200/JCO.2023.41.16_suppl.5550

Abstract #

5550

Poster Bd #

245

Abstract Disclosures

Similar Posters

First Author: Domenica Lorusso

First Author: Patricia Pautier

First Author: Isabelle Laure Ray-Coquard

First Author: Isabelle Ray-Coquard